SCHEMBL3883363

SCHEMBL3883363

NC(=O)c1ccc(N2CCCC2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.61
NPC1 O15118 5/20 0.61
RAB9A P51151 5/20 0.61
ALDH1A1 P00352 5/20 0.61
L3MBTL1 Q9Y468 4/20 0.61
HPGD P15428 3/20 0.61
TP53 P04637 3/20 0.61
ALOX15 P16050 3/20 0.61
TSHR P16473 2/20 0.61
LMNA P02545 2/20 0.61
SMN1; SMN2 Q16637 2/20 0.61
HSD17B10 Q99714 2/20 0.61
STAT1 P42224 1/20 0.61
HDAC6 Q9UBN7 1/20 0.61
KDM4E B2RXH2 4/20 0.59
NPSR1 Q6W5P4 2/20 0.59
MAPK1 P28482 1/20 0.59
CASP1 P29466 1/20 0.59
CASP7 P55210 1/20 0.59
CHRNA7 P36544 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4873981 0.98 NPC1 (0.61) MAPTNPC1RAB9AALDH1A1L3MBTL1
SCHEMBL1397421 0.98 NPC1 (0.61) MAPTNPC1RAB9AALDH1A1L3MBTL1
SCHEMBL4767629 0.98 NPC1 (0.61) MAPTNPC1RAB9AALDH1A1L3MBTL1
Trifluoroacetic Acid SCHEMBL28744186 0.87 NPC1 (0.54) MAPTNPC1RAB9AALDH1A1L3MBTL1
SCHEMBL4985730 0.86 AKR1C3 (0.64) MAPTNPC1RAB9AALDH1A1L3MBTL1
SCHEMBL3822792 0.84 CHEK1 (0.63) MAPTNPC1RAB9AALDH1A1TP53
SCHEMBL28319150 0.84 NPC1 (0.58) MAPTNPC1RAB9AALDH1A1L3MBTL1
SCHEMBL1397706 0.84 GSK3B (0.62) MAPTNPC1RAB9AALDH1A1HPGD
SCHEMBL909632 0.83 MAPT (0.61) MAPTNPC1RAB9AALDH1A1L3MBTL1
Hydrochloric Acid SCHEMBL3214277 0.83 CHRNB2 (0.62) MAPTNPC1RAB9AALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3275440-B1 NOVEL OXADIAZOLE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME NAT CT GERIATRICS & GERONTOLOGY (JP) 2022-05-04 EP claimed
US-12570645-B2 Uses of p53 x-ray co-crystal structures PMV PHARMACEUTICALS, INC. (US) 2026-03-10 US disclosed
US-20260027097-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS INC (US) 2026-01-29 US disclosed
EP-4642766-A1 COMPOUNDS AND METHODS FOR TREATING CANCER THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-11-05 EP disclosed
US-20250319063-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION PMV PHARMACEUTICALS, INC. 2025-10-16 US disclosed
US-12419880-B2 Companion diagnostic tool for mutant p53 reactivating compounds PMV PHARMACEUTICALS, INC. (US) 2025-09-23 US disclosed
EP-4559902-A2 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE Imago Biosciences Inc. (US) 2025-05-28 EP disclosed
EP-3256218-B1 A KDM1A INHIBITOR AND ITS USE IN THERAPY IMAGO BIOSCIENCES INC (US) 2024-12-11 EP disclosed
CN-115151252-B Iron death inhibitor-diarylamine acetamides 维泰瑞隆有限公司 2024-08-27 CN disclosed
US-20240269126-A1 COMBINATION THERAPY FOR TREATMENT OF CANCER PMV PHARMACEUTICALS, INC. 2024-08-15 US disclosed
EP-1893214-A1 SYNERGISTIC MODULATION OF FLT3 KINASE USING ALKYLQUINOLINES AND ALKYLQUINAZOLINES JANSSEN PHARMACEUTICA N.V. (BE) 2008-03-05 EP disclosed
EP-1893598-A1 ALKYLQUINOLINE AND ALKYLQUINAZOLINE KINASE MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2008-03-05 EP disclosed
US-20070021435-A1 AMINOPYRIMIDINES AS KINASE MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-01-25 US disclosed
US-20070004660-A1 Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines JANSSEN PHARMACEUTICA, N.V. (BE) 2007-01-04 US disclosed
WO-2006135719-A1 AMINOPYRIMIDINES AS KINASE MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2006-12-21 WO disclosed
WO-2006135713-A2 SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOPYRIMIDINES KINASE MODULATORS AND A FARNESYL TRANSFERASE INHIBITOR JANSSEN PHARMACEUTICA N.V. (BE) 2006-12-21 WO disclosed
WO-2006135629-A1 SYNERGISTIC MODULATION OF FLT3 KINASE USING ALKYLQUINOLINES AND ALKYLQUINAZOLINES JANSSEN PHARMACEUTICA N.V. (BE) 2006-12-21 WO disclosed
WO-2006135721-A1 ALKYLQUINOLINE AND ALKYLQUINAZOLINE KINASE MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2006-12-21 WO disclosed
US-20060281755-A1 SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOPYRIMIDINES KINASE MODULATORS BAUMANN CHRISTIAN A 2006-12-14 US disclosed
US-20060281772-A1 ALKYLQUINOLINE AND ALKYLQUINAZOLINE KINASE MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2006-12-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060281772-A1 ALKYLQUINOLINE AND ALKYLQUINAZOLINE KINASE MODULATORS FLT3, KIT, NTRK2 MAPT 3562/4885NPC1 2872/4885RAB9A 2300/4885
US-20250319063-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION TP53, TP53BP1, KRAS MAPT 4217/4885NPC1 2254/4885RAB9A 2434/4885
US-20070004660-A1 Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines FLT3, MCL1, CDC42BPG MAPT 4814/4885NPC1 766/4885RAB9A 2826/4885
US-20260027097-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, BRCA1 MAPT 1442/4885NPC1 3278/4885RAB9A 284/4885
US-12570645-B2 Uses of p53 x-ray co-crystal structures TP53, TP53BP1, ERCC2 MAPT 4207/4885NPC1 2874/4885RAB9A 1423/4885
US-20240269126-A1 COMBINATION THERAPY FOR TREATMENT OF CANCER TP53, KRAS, TP53BP1 MAPT 4445/4885NPC1 3401/4885RAB9A 2955/4885
US-12419880-B2 Companion diagnostic tool for mutant p53 reactivating compounds TP53, TP53BP1, KRAS MAPT 3530/4885NPC1 3688/4885RAB9A 809/4885
US-20070021435-A1 AMINOPYRIMIDINES AS KINASE MODULATORS FLT3, KIT, TK1 MAPT 3037/4885NPC1 4444/4885RAB9A 3444/4885
US-20060281755-A1 SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOPYRIMIDINES KINASE MODULATORS FLT3, CSF3R, CSF1R MAPT 4550/4885NPC1 1598/4885RAB9A 3186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.